The Patna High Court in the case Rajeev Kumar vs. The State of Bihar & Ors observed and has directed the State to file an affidavit within the period of three weeks, wherein stating that the actions taken to appoint members to the State Scheduled Caste Commission, State Schedule Tribes Commission, Mahadalit Commission, and the State Commission for Women in Bihar.
The Division bench comprising of Chief Justice K. Vinod Chandran and Justice Partha Sarthy in its order stated wherein the plea is moved by the Rajeev Kumar, a social activist and member of the Schedule Caste category, seeking expeditious appointments in order to fill the vacant posts in these commissions.
It has also been stated that as per the plea, the State Scheduled Caste Commission in Bihar has been functioning without any members or a chairman since the month of May 2016.
The petition filed stated that the State Women Commission has been operating without any members or a chairman since November 2020 and State Mahadalit Commission has been functioning with a joint secretary but without any members or chairman since the year 2017.
As per the plea, the State Scheduled Tribe Commission has also been without members and without the vice-chairman since 2018.
Accordingly, the court listed the matter for further consideration on August 04, 2023.
The counsel, Advocate, Mr. Vikash Kumar Pankaj appeared for the petitioners.
The counsel, AC to AG, Mr. P.K. Shahi, AG Mr. Amit Kumar represented the respondent.
Mark Zuckerberg's remark about India's 2024 elections, facing backlash from officials who emphasized the government’s…
Delhi Congress president Devender Yadav, accompanied by Jharkhand Minister for Panchayati Raj Dipika Pandey Singh,…
The relationship between gut microbes, hormones, and dietary preferences is a fascinating area of study…
AI systems like ChatGPT have been linked to environmental concerns, with reports showing their significant…
Rabi Lamichhane, RSP chief and ex-home minister, secures bail in the Swarnalakshmi Cooperative fraud case…
Metformin, the widely prescribed drug for managing type 2 diabetes, has recently gained attention for…